Today's Daily Dose brings you news about disappointing phase II trial results of Conatus; follow-on offering of Cellectis; near-term catalysts of Eleven Biotherapeutics; Paratek's date with FDA, and Lilly's REACH-2 liver cancer trial results.
Original Article: CNAT Disappoints, EBIO To Report VISTA Data In May, PRTK To Face FDA In Oct.